Literature DB >> 31131305

Targeting HER2 beyond breast cancer.

Sanchita Bhatnagar1, Jogender Tushir-Singh2.   

Abstract

The structural basis of blocking human epidermal growth factor receptor-2 (HER2) dimerization remains of great interest to generate effective anti-cancer therapies. Despite clinically feasible outcome in mammary tumors, a fine consensus between efficacy and safety remains a critical challenge beyond breast cancer. Here we extrapolate on the balancing act using recently reported clinical findings in salivary ductal carcinomas.

Entities:  

Keywords:  Targeted therapies; cancer; immunotherapy

Year:  2019        PMID： 31131305      PMCID： PMC6512921          DOI： 10.1080/23723556.2019.1571984

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

1.  Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Authors:  José Baselga; Javier Cortés; Sung-Bae Kim; Seock-Ah Im; Roberto Hegg; Young-Hyuck Im; Laslo Roman; José Luiz Pedrini; Tadeusz Pienkowski; Adam Knott; Emma Clark; Mark C Benyunes; Graham Ross; Sandra M Swain
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

Review 2.  Do Asian patients have worse lupus?

Authors:  M Y Mok; W L Li
Journal:  Lupus       Date:  2010-10       Impact factor: 2.911

3.  Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice.

Authors:  Megan Lo; Hok Seon Kim; Raymond K Tong; Travis W Bainbridge; Jean-Michel Vernes; Yin Zhang; Yuwen Linda Lin; Shan Chung; Mark S Dennis; Y Joy Yu Zuchero; Ryan J Watts; Jessica A Couch; Y Gloria Meng; Jasvinder K Atwal; Randall J Brezski; Christoph Spiess; James A Ernst
Journal:  J Biol Chem       Date:  2017-01-11       Impact factor: 5.157

4.  Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.

Authors:  Bertrand Routy; Emmanuelle Le Chatelier; Lisa Derosa; Connie P M Duong; Maryam Tidjani Alou; Romain Daillère; Aurélie Fluckiger; Meriem Messaoudene; Conrad Rauber; Maria P Roberti; Marine Fidelle; Caroline Flament; Vichnou Poirier-Colame; Paule Opolon; Christophe Klein; Kristina Iribarren; Laura Mondragón; Nicolas Jacquelot; Bo Qu; Gladys Ferrere; Céline Clémenson; Laura Mezquita; Jordi Remon Masip; Charles Naltet; Solenn Brosseau; Coureche Kaderbhai; Corentin Richard; Hira Rizvi; Florence Levenez; Nathalie Galleron; Benoit Quinquis; Nicolas Pons; Bernhard Ryffel; Véronique Minard-Colin; Patrick Gonin; Jean-Charles Soria; Eric Deutsch; Yohann Loriot; François Ghiringhelli; Gérard Zalcman; François Goldwasser; Bernard Escudier; Matthew D Hellmann; Alexander Eggermont; Didier Raoult; Laurence Albiges; Guido Kroemer; Laurence Zitvogel
Journal:  Science       Date:  2017-11-02       Impact factor: 47.728

5.  Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct Carcinoma.

Authors:  Hideaki Takahashi; Yuichiro Tada; Takashi Saotome; Kohei Akazawa; Hiroya Ojiri; Chihiro Fushimi; Tatsuo Masubuchi; Takashi Matsuki; Kaori Tani; Robert Y Osamura; Hideaki Hirai; Shuhei Yamada; Daisuke Kawakita; Kouki Miura; Shin-Etsu Kamata; Toshitaka Nagao
Journal:  J Clin Oncol       Date:  2018-11-19       Impact factor: 44.544

6.  A Single-Agent Dual-Specificity Targeting of FOLR1 and DR5 as an Effective Strategy for Ovarian Cancer.

Authors:  Gururaj Shivange; Karol Urbanek; Piotr Przanowski; Justin S A Perry; James Jones; Robert Haggart; Christina Kostka; Tejal Patki; Edward Stelow; Yuliya Petrova; Danielle Llaneza; Marty Mayo; Kodi S Ravichandran; Charles N Landen; Sanchita Bhatnagar; Jogender Tushir-Singh
Journal:  Cancer Cell       Date:  2018-08-13       Impact factor: 31.743

7.  Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients.

Authors:  Branka Petricevic; Johannes Laengle; Josef Singer; Monika Sachet; Judit Fazekas; Guenther Steger; Rupert Bartsch; Erika Jensen-Jarolim; Michael Bergmann
Journal:  J Transl Med       Date:  2013-12-12       Impact factor: 5.531

8.  A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study.

Authors:  Begoña Martin-Castillo; Sonia Pernas; Joan Dorca; Isabel Álvarez; Susana Martínez; Jose Manuel Pérez-Garcia; Norberto Batista-López; César A Rodríguez-Sánchez; Kepa Amillano; Severina Domínguez; Maria Luque; Agostina Stradella; Idoia Morilla; Gemma Viñas; Javier Cortés; Elisabet Cuyàs; Sara Verdura; Álvaro Fernández-Ochoa; Salvador Fernández-Arroyo; Antonio Segura-Carretero; Jorge Joven; Elsa Pérez; Neus Bosch; Margarita Garcia; Eugeni López-Bonet; Samiha Saidani; Maria Buxó; Javier A Menendez
Journal:  Oncotarget       Date:  2018-11-02

Review 9.  A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer.

Authors:  James D Mellor; Michael P Brown; Helen R Irving; John R Zalcberg; Alexander Dobrovic
Journal:  J Hematol Oncol       Date:  2013-01-04       Impact factor: 17.388

10.  Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes.

Authors:  N Tsavaris; C Kosmas; M Vadiaka; P Kanelopoulos; D Boulamatsis
Journal:  Br J Cancer       Date:  2002-07-01       Impact factor: 7.640
  10 in total
  1 in total

1.  Key genes and drug delivery systems to improve the efficiency of chemotherapy.

Authors:  Zally Torres-Martinez; Yamixa Delgado; Yancy Ferrer-Acosta; Ivette J Suarez-Arroyo; Freisa M Joaquín-Ovalle; Louis J Delinois; Kai Griebenow
Journal:  Cancer Drug Resist       Date:  2021-03-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.